Meticulous Research®, a renowned global market research entity, proudly unveils its latest research report titled 'Europe In Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, PoC) - Forecast to 2030.’
Download Sample Report Here : https://www.meticulousresearch.com/download-sample-report/cp_id=5718
In this cutting-edge publication, Meticulous Research® projects that the Europe In Vitro Diagnostics (IVD) market is poised to achieve an impressive valuation of $39.77 billion by 2030, reflecting a noteworthy Compound Annual Growth Rate (CAGR) of 3.7% from 2023 to 2030. The report attributes the burgeoning growth of the Europe IVD market to various factors, including the escalating prevalence of chronic diseases, a burgeoning geriatric population, an upswing in infectious diseases, a surge in demand for point-of-care (PoC) and rapid diagnostics, heightened awareness regarding early disease diagnosis, increased healthcare expenditures, and augmented funding for research activities. However, challenges such as stringent technical requirements and regulatory processes for high/moderate-complexity tests, along with the variability in test results observed in rapid IVD tests, pose constraints to the market's growth. The report also underscores the emergence of personalized medicine and advancements in genomics and proteomics as pivotal growth opportunities for market players, albeit against the backdrop of an evolving regulatory landscape.
Key Players:
Leading the way in the Europe IVD market are key players, including Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).
Europe IVD Market: Future Outlook
The comprehensive segmentation of the Europe IVD market encompasses Offering (Kits & Reagents, Systems, and Software & Services), Technology (Immunoassay/Immunochemistry, Biochemistry/Clinical Chemistry, Molecular Diagnostics, Point of Care (POC) Diagnostics, Whole Blood Glucose Monitoring, Microbiology, Hematology, Coagulation/Hemostasis, Urinalysis, and Other Technologies), Application (Infectious Diseases, Oncology, Diabetes, Cardiology, Nephrology, Autoimmune Disorders, and Other Applications), Diagnostic Approach (Lab Testing, OTC/Self-testing, and Point of Care Testing), and End User (Diagnostic Laboratories, Hospitals & Clinics, Home Healthcare, and Other End Users), across various European countries. The report also includes an in-depth analysis of industry competitors and their market share at the country level.
Speak to Analyst : https://www.meticulousresearch.com/speak-to-analyst/cp_id=5718
Key Highlights and Segment Analysis:
Offering:
• Kits & Reagents
• Systems
• Software & Services
In 2023, the kits & reagents segment is anticipated to experience the highest CAGR. This growth can be attributed to continuous advancements in reagents and kits development, the adoption of IVD kits for disease diagnosis, and the ease of use, reflecting the increasing demand for consumables. The rising trend of self-testing and the adoption of POC diagnostic testing further contribute to the dominance of this segment.
Technology:
• Immunoassay/Immunochemistry
• Biochemistry/Clinical Chemistry
• Molecular Diagnostics
• Point of Care (POC) Diagnostics
• Whole Blood Glucose Monitoring
• Microbiology
• Hematology
• Coagulation/Hemostasis
• Urinalysis
• Other Technologies
In 2023, the molecular diagnostics segment is expected to command the largest market share. The prevalence of communicable and non-communicable diseases, the growth in the geriatric population, and the introduction of advanced molecular diagnostic techniques contribute to the dominance of this segment. Notably, advancements such as Nucleic Acid Amplification Testing (NAAT) enhance accessibility for high-volume testing with improved specificity.
Application:
• Infectious Diseases
• Oncology
• Diabetes
• Cardiology
• Nephrology
• Autoimmune Disorders
• Other Applications

Request Sample Report : https://www.meticulousresearch.com/request-sample-report/cp_id=5718
In 2023, the infectious disease segment is poised to lead the Europe IVD market. Categorically, infectious diseases include respiratory infections (excluding influenza), hepatitis, HIV, HAIs, tropical diseases, influenza, sexually transmitted diseases (STDs), and other infectious diseases. The increasing prevalence of healthcare-associated infections (HAIs) and STDs drives demand for IVD testing. For instance, the UK Health Security Agency (UKHSA) reported a 24% increase in sexually transmitted infections (STIs) in the U.K. in 2022 compared to 2021.
Diagnostic Approach:
• Lab Testing
• OTC/Self-testing
• Point of Care Testing
The point-of-care testing segment is anticipated to witness the highest CAGR during the forecast period. The growth of POC testing can be attributed to the increasing prevalence of chronic diseases, innovations in PoC tests, the development of CLIA-waived PoC tests, and the shortage of skilled technicians for conducting lab tests.
End User:
• Diagnostic Laboratories
• Hospitals & Clinics
• Home Healthcare
• Other End Users
In 2023, hospitals & clinics are expected to account for the largest share of the Europe IVD market. Hospitals and clinics play a crucial role in conducting a wide range of tests to diagnose various medical conditions, ensuring effective clinical planning for treatment and prevention. The surge in hospital admissions during the COVID-19 pandemic further amplified the demand for diagnostic products.
Geographic Overview: This research meticulously evaluates major European countries, including Germany, the U.K., France, Italy, Spain, Switzerland, Netherlands, Denmark, and the Rest of Europe. In 2023, Germany is expected to dominate the Europe IVD market, fueled by rising chronic disease prevalence, a growing geriatric population, government support for routine tests, and a high incidence of healthcare-associated infections (HAIs). Public reimbursement for biomarker testing in Germany further supports market growth.
Quick Buy : https://www.meticulousresearch.com/Checkout/26595514
Key Questions Addressed in the Report:
• Which market segments present high-growth potential concerning offering, technology, application, diagnostic approach, end user, and country?
• What does the historical trajectory of IVD testing in Europe reveal?
• What are the market forecasts and estimates for the period 2023–2030?
• What are the major drivers, restraints, challenges, and opportunities shaping the Europe IVD market?
• Who are the major players in the Europe IVD market?

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research